NFA
GTHX

Nationwide Fund Advisors’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Nationwide Fund Advisors’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-3,574
Closed -$89K – 2253
2017
Q3 		$89K Buy
+3,574
New +$66K ﹤0.01% 2946

Other funds holding GTHX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

Nationwide Fund Advisors's GTHX Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q4 2017, closing a stake of 3,574 shares — an estimated $89K sold.

Nationwide Fund Advisors first reported a position in GTHX in Q3 2017 and held it in 1 quarter. The position peaked at $89K in Q3 2017. 57 funds tracked by Wall St. Rank hold GTHX as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 3,574 G1 Therapeutics, Inc. Common Stock shares in Q4 2017, an estimated $89K.
  • Nationwide Fund Advisors first reported a position in G1 Therapeutics, Inc. Common Stock in Q3 2017 and held it in 1 quarter.
  • Nationwide Fund Advisors's G1 Therapeutics, Inc. Common Stock position peaked at $89K in Q3 2017.
  • 57 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.